Playback speed
10 seconds
ESMO 2023 Insights: "The NICHE-3 Study on Neoadjuvant Nivo + Relatlimab (anti-LAG3) in Locally Advanced MMR-Deficient Colon Cancers"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Yara Verschoor
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Yara Verschoor
0 views
October 31, 2023
Comments 0
Login to view comments.
Click here to Login